Ascelia Pharma
Ascelia Pharma re-evaluation outcome: SPARKLE meet primary endpoints (Redeye)
2024-05-02 13:58
Orviglance meets the primary endpoint in the SPARKLE study with a p-value of <0.001. Equally important in this situation is that ” The reliability of the data is solid and conclusive for all readers – this includes an acceptable level of variability”. We look forward to further details and clarifications on the call scheduled for 7 May (CET 14.00).
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se